ValuEngine upgraded shares of Abeona Therapeutics (NASDAQ:ABEO) from a hold rating to a buy rating in a research report report published on Friday.

Several other equities research analysts have also recently weighed in on ABEO. HC Wainwright reiterated a buy rating and issued a $30.00 price objective on shares of Abeona Therapeutics in a report on Friday. Zacks Investment Research cut Abeona Therapeutics from a hold rating to a sell rating in a report on Friday, November 16th. Cantor Fitzgerald reiterated a buy rating and issued a $36.00 price objective on shares of Abeona Therapeutics in a report on Thursday. BidaskClub cut Abeona Therapeutics from a hold rating to a sell rating in a report on Thursday, October 4th. Finally, Maxim Group reiterated a buy rating and issued a $35.00 price objective on shares of Abeona Therapeutics in a report on Friday, August 10th. Two analysts have rated the stock with a sell rating and ten have issued a buy rating to the company. Abeona Therapeutics has a consensus rating of Buy and a consensus target price of $26.78.

ABEO stock traded up $0.39 during trading on Friday, hitting $8.54. 1,119,203 shares of the company traded hands, compared to its average volume of 594,866. Abeona Therapeutics has a 1 year low of $6.94 and a 1 year high of $22.00. The stock has a market capitalization of $390.75 million, a PE ratio of -12.94 and a beta of 1.81.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings data on Monday, November 12th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.11). Abeona Therapeutics had a negative return on equity of 27.69% and a negative net margin of 843.14%. The business had revenue of $1.71 million during the quarter, compared to analysts’ expectations of $1.02 million. Research analysts anticipate that Abeona Therapeutics will post -0.98 EPS for the current fiscal year.

Several large investors have recently made changes to their positions in ABEO. TD Asset Management Inc. raised its position in shares of Abeona Therapeutics by 151.4% in the 2nd quarter. TD Asset Management Inc. now owns 81,691 shares of the biopharmaceutical company’s stock worth $1,307,000 after acquiring an additional 49,200 shares in the last quarter. BlackRock Inc. raised its position in shares of Abeona Therapeutics by 16.6% in the 2nd quarter. BlackRock Inc. now owns 2,184,506 shares of the biopharmaceutical company’s stock worth $34,951,000 after acquiring an additional 311,034 shares in the last quarter. FMR LLC raised its position in shares of Abeona Therapeutics by 47.7% in the 2nd quarter. FMR LLC now owns 7,094,307 shares of the biopharmaceutical company’s stock worth $113,509,000 after acquiring an additional 2,291,016 shares in the last quarter. Altshuler Shaham Ltd raised its position in shares of Abeona Therapeutics by 72.2% in the 2nd quarter. Altshuler Shaham Ltd now owns 63,700 shares of the biopharmaceutical company’s stock worth $1,019,000 after acquiring an additional 26,700 shares in the last quarter. Finally, Bank of America Corp DE raised its position in shares of Abeona Therapeutics by 547.4% in the 2nd quarter. Bank of America Corp DE now owns 92,879 shares of the biopharmaceutical company’s stock worth $1,486,000 after acquiring an additional 78,533 shares in the last quarter. 72.32% of the stock is owned by hedge funds and other institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Further Reading: Are analyst ratings accurate?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.